Skip to main content

Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Maximizing Transplant Eligibility

Recorded on: October 25, 2022

Click Here to Participate 

Estimated Time: 0.5 hour
CME & CE Activity Release Date: November 30, 2022
CME & CE Credit Valid Through: November 30, 2023 
0.5 CME/CE Credit/Contact Hour for physicians and registered nurses. 
Non-interactive recorded webinar 


Target Audience

This activity is intended for hematologists/oncologists, nurses, nurse practitioners, and advanced practice nurses.



Join our experts as they discuss strategies to enhance transplant eligibility in patients with relapsed or refractory acute lymphoblastic leukemia. Topics of discussion include the role of transplant in patient management, the impact of prior therapies on transplant eligibility, and recommendations for management of adverse events (AEs) of treatments to improve transplant eligibility.


Learning Objectives

After completing this CE activity, the participant should be better able to: 

  • Have increased knowledge regarding the AEs associated with therapies used to treat adults with R/R ALL
  • Have greater competence related to managing AEs of R/R ALL therapies in adults
  • Demonstrate greater confidence in their ability to work collaboratively as a member of the healthcare team to mitigate AEs associated with R/R ALL therapies in adults in order to enhance transplant eligibility



Nicholas Short, MD
Assistant Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Shemeka Fransaw, APRN
Department of Leukemia
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas


Continuing Education Information


Accreditation Statement Logos

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE) credit

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

For Nurses
Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

There are no fees for participating in or receiving credit for this activity.

This activity is developed through a collaboration between The Leukemia & Lymphoma Society and Medscape Oncology.

This activity is supported by an independent educational grant from Amgen.


Click Here to Participate 

Participants gain access to the webinar via the participation button above.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at


< Back to Continuing Education